triptorelin pamoate

triptorelin pamoate

Decapeptyl SR (UK), Gonapeptyl Depot (UK), Trelstar Depot, Trelstar LA

Pharmacologic class: Synthetic agonist analog of luteinizing hormone-releasing hormone (LHRH)

Therapeutic class: Antineoplastic

Pregnancy risk category X

Action

Initially causes surge in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. After several weeks of therapy, LH and FSH secretion decrease, causing sustained testosterone reduction equivalent to pharmacologic castration.

Availability

Microgranules for injection (lyophilized): 3.75 mg (depot), 11.25 mg (long-acting), 22.5 mg (long-acting)

Indications and dosages

Palliative treatment of advanced prostate cancer

Adults: 3.75 mg (depot) I.M. monthly as a single injection or 11.25 mg (long-acting) I.M. q 12 weeks as a single injection or 22.5 mg (long-acting) I.M. q 24 weeks

Off-label uses

• Infertility

• Endometriosis

• Uterine fibroids

• Precocious puberty

Contraindications

• Hypersensitivity to drug, LHRH, or other LHRH agonists

• Pregnancy

• Women of childbearing potential

Precautions

Use cautiously in:

• renal insufficiency

• prostate cancer with impending spinal cord compression or severe urinary tract disorder

• breastfeeding patients (use not recommended).

Administration

• Reconstitute with 2 ml of sterile water for injection, using accompanying syringe (don't use other diluents). Add syringe contents to vial containing particles; shake well. Withdraw vial contents and inject I.M. immediately.

• Inject deep I.M. into either buttock. Rotate injection sites.

Keep epinephrine and emergency equipment at hand in case of anaphylactic reaction.

Adverse reactions

CNS: insomnia, dizziness, headache, emotional lability, fatigue, stroke

CV: hypertension, increased risk of myocardial infarction and sudden cardiac death

GI: vomiting, diarrhea

GU: urinary retention, urinary tract infection, gynecomastia, erectile dysfunction, testicular atrophy

Hematologic: anemia

Metabolic: hyperglycemia

Musculoskeletal: skeletal or leg pain

Skin: pruritus

Other: leg edema, temporary worsening of disease, edema, hot flashes, pain at injection site, hypersensitivity reactions including anaphylaxis

Interactions

Drug-diagnostic tests. Hemoglobin: decreased value

Pituitary-gonadal function tests: misleading results (with continuous or long-term use)

Serum glucose: increased

Patient monitoring

• Monitor serum testosterone and prostate-specific antigen levels periodically to assess drug efficacy.

Monitor patient for signs and symptoms suggestive of cardiovascular disease and manage as appropriate.

Patient teaching

• Explain drug therapy to patient. Stress need for follow-up laboratory tests.

• Tell patient prostate cancer symptoms may worsen during first few weeks of therapy.

• Instruct patient to monitor weight and report sudden weight gain or leg swelling.

• Advise female patient to tell prescriber before starting therapy if she is or plans to become pregnant. Caution her not to breastfeed during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
References in periodicals archive ?
Decapeptyl (triptorelin pamoate) is an agonist analogue of the natural gonadotropin-releasing hormone, currently available in three sustained-release formulations (1, 3 and 6 months).
It was reported yesterday that the collaboration is aimed at providing triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary cancer participating in a clinical study sponsored by the EORTC.
Therefore, this study was designed to compare patients' as well as health care providers' perceptions of injection site tolerability following the IM injection of triptorelin pamoate or SC injection of leuprolide.
During the first study period, patients were randomized 1:1 to receive a single injection of triptorelin pamoate 22.5 mg mixed with 2 mL sterile water administered intramuscularly in either buttock as specified in the prescribing information (Trelstar PI, 2013) or leuprolide acetate 45 mg mixed liquid in a prefilled delivery system administered subcutaneously in the upper- or mid-abdominal area.
Looking at the use of triptorelin pamoate (Trelstar), goserelin acetate implant (Zoladex), and leuprolide acetate suspension (Lupron, Eligard), the OIG found that physicians favored the use of the more expensive drugs while the least costly alternative policies were in place, but that their use was slowly declining.
Looking at the use of triptorelin pamoate (Trelstar), goserelin acetate implant (Zoladex), and leuprolide acetate suspension (Lupron, Eligard), the OIG found that physicians favored use of the more expensive drugs while the least costly alternative policies were in place but that their use was slowly declining.
Products successfully registered and launched include oxaliplatin for advanced colorectal cancer and triptorelin pamoate for prostate cancer, both market leaders in their therapeutic areas.
Ipsen, a France-based pharmaceutical company, has met its primary endpoints in the Phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25mg, administered subcutaneously in patients with locally advanced or metastatic prostate cancer, it was reported yesterday.
The trial assessed the efficacy, safety and local tolerability of a three-month triptorelin pamoate (11.25mg) given subcutaneously to patients.
The company is studying the efficacy and safety of the gonadotropin releasing hormone agonist, analogue triptorelin pamoate six-month formulation, in the treatment of children suffering from central (GnRH-dependent) precocious puberty.
The study is an international, multicentre, non-controlled phase III study on the efficacy, pharmacokinetics and safety of two consecutive intramuscular injections of the triptorelin pamoate 22.5mg six-month formulation over 12 months.
Three slow-release formulations (one, three and six months) of triptorelin pamoate has been developed.